Skip to main content
    G

    Genmab AS (GMAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $51.96
    +0.39 (+0.76%)

    Market Cap: $31.80B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Genmab AS (GMAB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Genmab AS (GMAB) has a market cap of $31.80B. Its trailing P/E is 36.1x.

    Total Valuation

    Market Cap$31.80B
    Latest price (Nov 17, 2026)$51.96

    Key Dates

    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.58% in the quarter ended Sep 30, 2026 and shrank 2.19% a year over 2 years.

    Shares Outstanding620.69M
    Shares Change (YoY)-0.01%
    Shares Change (QoQ)+0.58%
    Share Count Growth (2Y CAGR)-2.19%

    Valuation Ratios

    Sales and book value multiples are 19.3x and 5.1x.

    P/E Ratio36.1x
    P/S Ratio19.3x
    P/B Ratio5.1x
    P/FCF Ratio57.5x
    PEG Ratio5.6

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 58.8x EBITDA and 63.0x free cash flow.

    EV / EBITDA58.8x
    EV / FCF63.0x

    Price Statistics

    The stock is up 71.71% over 52 weeks and trades 24.07% above its 50-day average.

    Beta (1Y)0.89
    52-Week Change+71.71%
    1-Month Change+34.96%
    3-Month Change+52.33%
    6-Month Change+102.34%
    5-Year Change+27.82%
    10-Year Change+242.21%
    Total Return (1Y)+71.71%
    Total Return (3Y CAGR)+16.57%
    Total Return (5Y CAGR)+4.17%
    Return vs SPY (1Y)+59.81%
    Max Drawdown (1Y)-32.51%
    Max Drawdown (3Y)-45.13%
    Sharpe Ratio (1Y)1.24
    Correlation with SPY (1Y)0.28
    50-Day Average$41.88
    200-Day Average$31.73
    52-Week Range$23.62 to $59.97
    RSI (14 Days)60.4
    Average Volume (20 Days)6.43M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.45x current liabilities, and total debt is 0.79x shareholder equity.

    Current Ratio2.45x
    Quick Ratio2.43x
    Debt / Equity0.79x
    Debt / EBITDA8.29x
    Interest Coverage3.76x

    Returns and Efficiency

    Return on invested capital is 4.83% over the last 12 months, against a 5-year average of 15.55%.

    Return on Assets (ROA)3.10%
    Return on Invested Capital (ROIC)4.83%
    ROIC (5Y Average)15.55%
    Inventory Turnover7.55x
    Receivables Turnover2.23x

    Scores

    GMAB has an Altman Z-Score of 3.90, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score3.90
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Dividends and Yields

    GMAB does not pay a dividend. Its free cash flow yield is 1.74%.

    Earnings Yield2.77%
    FCF Yield1.74%

    Stock Splits

    The last split was a 5-for-1 forward split on May 1, 2018.

    Last Split DateMay 1, 2018
    Split TypeForward split
    Split Ratio5:1

    Peer Position

    Against 5 similar companies, GMAB has the 2nd highest P/E.

    P/E Ratio36.1x vs 19.7x median
    P/S Ratio19.3x vs 16.7x median
    ROIC4.83% vs -12.70% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GMAB

    What is GMAB's market cap?

    Genmab AS has a market cap of $31.80B.

    What is GMAB's P/E ratio?

    Genmab AS has a trailing P/E ratio of 36.1x.

    How many shares of GMAB are outstanding?

    Genmab AS has 620.69M shares outstanding. The count is down 0.01% from a year earlier.

    Does GMAB pay a dividend?

    No. Genmab AS does not pay a dividend.